title: Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
authors.affiliation: Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris VII Diderot, Clichy, France mohamed.bouattour@bjn.aphp.fr.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Bouattour
authors.affiliation: Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil Université, INSERM U 955 Team 18, Paris, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Rousseau
authors.affiliation: Pitié-Salpêtrière University Hospital, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie Paris VI, Paris, France.
authors.forename: Johanna
authors.initials: J
authors.lastname: Wassermann
authors.affiliation: Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris VII Diderot, Clichy, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Payancé
authors.affiliation: Angiogenesis Inhibitors Multidisciplinary Study Group, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Huillard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide